Interesting Response to Article in NJEM on HPV Vaccine

New England Journal of Medicine

Volume 361:1610-1611
October 15, 2009
Number 16

To the Editor: In her review of human papillomavirus (HPV) vaccination (July 16 issue),1 Kahn neglects to discuss one key “area of uncertainty,” namely, the extent to which other high-risk oncogenic HPV types may rapidly occupy the epidemiologic niche vacated by vaccine-targeted HPV types 16 and 18. If this rapid occupation occurs, the large expenditure of health care dollars for widespread HPV vaccination would be rendered futile.

Steven Leiner, N.P.
Mission Neighborhood Health Center
San Francisco, CA

Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med 2009;361:271-278.


Comment from Leslie

Aaah, virus – mutating little buggers….Finally people are waking up and smelling the coffee.


Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.